With the Cavalry now coming over the hill its time for Open Orphan to kick on…
“…Can we grow the Open Orphan Share price by over 50% every six months….yes we can…”
Here, Jeremy Naylor of IGTV catches up with Executive Chairman of Open Orphan Cathal Friel.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.
Cathal opens up to Jeremy in this very revealing interview and covers how business will progress in a post covid world. With the “Cavalry coming over the hill” in the form of not one but three experimental vaccines against Covid 19 which path does Cathal lead his Team down now? We have survived the “Covid pop” and this latest shakeout is really separating the “men-from -the-boys” as to who has contracts, who is profitable and who has cash on the balance sheet.
Cathal explains about how the cash in the companies account is the shareholders, how he plans to reward shareholders, a possible Dividend ahead and definitely no more fundraising plans. “Will you be taken over or maybe keep the company?” asks Jeremy
…Catch the interview below to find out the answer!!